Postdoctoral researcher in Precision Cancer Medicine

Karolinska Institutet, Department of Oncology-Pathology, Forskargrupp Kallioniemi

At the Department of Oncology-Pathology basic, translational and clinical research and educational activities related to cancer is carried out. Approximately 300 people from over 40 nations are currently working at the department. About 30 research groups with various cancer research profiles are involved and we have around 110 PhD students. The Department of Oncology-Pathology is responsible for undergraduate courses in Pathology, Oncology and Forensic Medicine for medical students, as well as for Tumor biology courses for biomedicine students and Pathology courses for opticians.

Research group Olli Kallioniemi
This position resides in the research group of Olli Kallioniemi, Director of Science for Life Laboratory, Professor of Molecular Precision Medicine, affiliated with both the Dept. Oncology and Pathology, Karolinska Institutet and the Science for Life Laboratory. The work will involve an exciting opportunity to practice precision cancer medicine research in a translational setting, with the aim to assign and optimize targeted treatments for individual cancer patients. Our disease focus is on acute myeloid leukemia (AML), ovarian and urological tumors (prostate, kidney and bladder). Our goal is to develop a systems biology framework to match targeted therapies and drug combinations using genomic, transcriptomic and proteomic profiling along with functional ex vivo drug testing on primary patient-derived cells (PDC) from cancer patients. We work through team science in close collaboration not only with other research groups, but also with clinicians, as well as with different technology platforms of the SciLifeLab. For more information : https://www.scilifelab.se/researchers/olli-kallioniemi/ 

Task Description
The tasks for this position involves the establishment of innovative drug testing assays in primary cell models, characterization of the models and integration of the datasets to inform patient treatment. The candidate is also expected to carry out project management tasks such as carrying out expected milestones within the project, budgeting and reporting as well as interacting not only with research but also clinical and pharma collaborators.

Qualifications
The successful candidate is expected to have a doctoral degree in biochemistry, biology, biotechnology, medicine or other relevant field. The candidate, is independent and motivated with a documented ability to carry out experimental research projects but also project management including excellent communication skills in spoken and written English. Previous expertize in primary model development from solid tumors and/or hematological cancers is beneficial. Experience with high throughput drug testing, assay development, high throughput high content microscopy and –omics technologies is highly valued. We stress research expertise and interest in collaborative science when assessing applicants.

Requirements:
– PhD in biochemistry, biology or medicine.
– Knowledge of cancer biology, precision cancer medicine and translational cancer research.
– Extensive experience in cell culture techniques, especially primary cell models. 
– Knowledge on high-throughput drug testing and assay development
– Experience in working as part of large multidisciplinary, collaborative research projects (“team science”).

Application process, salary and contract
An application must contain the following documents in English: Curriculum vitae, qualifications and description of planned research, presented in accordance with Karolinska Institutet’s qualifications portfolio. For more information: http://ki.se/qualificationsportfolio.

The application is to be submitted through the MyNetwork recruitment system. The salary is defined according to the KI salary system. The project is initially for one year contract with the possibility of extension with the preferred start date as soon as possible. SciLifelab
Science for Life Laboratory (www.scilifelab.se) is a leading national infrastructure for next-generation life science research in Sweden. SciLifeLab is jointly operated by the four host universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University, and it has facilities in four other universities across Sweden. There are over 1 000 people working at SciLifeLab, either in research groups or in the infrastructure facilities, most of them in the KI Solna campus and in Uppsala.

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Pursuant to the regulations of the Swedish National Archives, applications are kept on file for two years after the appointment has gained legal force. The regulations do not apply to attachments that have been printed or otherwise published.
Karolinska Institutet strives to provide a workplace that has approximately the same number of women and men, is free of discrimination and offers equal opportunity to everyone.
For temp agencies and recruiters, and to salespersons: We politely, yet firmly, decline direct contact with temp agencies and recruiters, as well as those selling additional job announcements.

Type of employmentTemporary position longer than 6 months
Contract typeFull time
Number of positions1
Working hours100%
CitySolna
CountyStockholms län
CountrySweden
Reference number2-4544/2019
ContactPäivi Östling, paivi.ostling@ki.se, +46 (0)73 673 5762
Union representativeAndreas Lundqvist, SACO, 46 8 517 76884Helen Eriksson, OFR, 08 517 762 79
Last application date10.Nov.2019 11:59 PM CET

Read the job desription on the university homepage

Login and apply

Post expires on Sunday November 10th, 2019